dipyridamole has been researched along with Diabetes Mellitus, Type 2 in 35 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| ", aspirin alone (330 mg 3 times daily) or in combination with dipyridamole (75 mg 3 times daily), was tested versus placebo in 475 patients with early diabetic retinopathy." | 9.06 | Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group. ( , 1989) |
| "We selected parameters (fibrinogen, micro/macroalbuminuria, ateroma in carotid artery bed) that were significantly associated with stress myocardial SPECT result." | 7.73 | [The meaning of the combination of fibrinogen, micro/macroalbuminuria and atheromatosis in the carotid bloodstream for the evaluation of the abnormal finding of the stress myocardial SPECT in the asymptomatic 2nd type diabetic patients]. ( Holá, D; Pálová, S; Zamrazil, V, 2006) |
| "A total of 5308 patients with type 2 diabetes were identified by the National Health Insurance from 1998 to 2000 and followed up until 2013." | 5.72 | Antiplatelet agents aspirin and dipyridamole, and the risk of different carcinoma in patients with type 2 diabetes mellitus: A Taiwan retrospective cohort study. ( Hsu, WH; Huang, HY; Lee, MY; Liang, HL; Lu, TW; Sung, YW, 2022) |
| "Myocardial ischemia is frequently asymptomatic, thus leading to a late diagnosis and worse prognosis." | 5.34 | Coronary artery disease in asymptomatic type-2 diabetic women. A comparative study between exercise test, cardiopulmonary exercise test, and dipyridamole myocardial perfusion scintigraphy in the identification of ischemia. ( Alves, A; Carvalho, AC; Mastrocolla, L; Meneghelo, R; Paola, AA; Piegas, LS; Rodrigues, F; Smanio, PE; Tebexreni, AS; Thom, A, 2007) |
| "In these NIDDM patients without evidence of epicardial coronary disease, endothelial dysfunction is strongly suggested by an impaired increase in CBF both to dipyridamole and to CPT." | 5.10 | Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction: a PET study of myocardial perfusion in diabetes. ( Hesse, B; Kjaer, A; Meyer, C; Nielsen, FS; Parving, HH, 2003) |
| ", aspirin alone (330 mg 3 times daily) or in combination with dipyridamole (75 mg 3 times daily), was tested versus placebo in 475 patients with early diabetic retinopathy." | 5.06 | Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group. ( , 1989) |
| "Dipyridamole/rest technetium 99m sestamibi imaging was performed in 33 patients with type 2 diabetes without a history of coronary artery disease and normal coronary vessels at angiography and in 12 control subjects." | 3.74 | Estimation of coronary flow reserve by sestamibi imaging in type 2 diabetic patients with normal coronary arteries. ( Cuocolo, A; Luongo, L; Pellegrino, T; Petretta, M; Sorrentino, AR; Storto, G, 2007) |
| "We selected parameters (fibrinogen, micro/macroalbuminuria, ateroma in carotid artery bed) that were significantly associated with stress myocardial SPECT result." | 3.73 | [The meaning of the combination of fibrinogen, micro/macroalbuminuria and atheromatosis in the carotid bloodstream for the evaluation of the abnormal finding of the stress myocardial SPECT in the asymptomatic 2nd type diabetic patients]. ( Holá, D; Pálová, S; Zamrazil, V, 2006) |
| "To clarify if coronary flow reserve (CFR) is related to insulin resistance or hyperglycemia in normotensive NIDDM, myocardial blood flow (MBF) at baseline and during dipyridamole loading were measured with 13N-ammonia positron-emission tomography." | 3.70 | Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM. ( Momomura, S; Nishikawa, J; Ohtake, T; Omata, M; Sasaki, Y; Woo-Soo, S; Yokoyama, I; Yonekura, K, 1998) |
| " Moreover, patients without any history of coronary heart disease and showing a normal resting ECG underwent a bicycle exercise test or a dipyridamole thallium scintigraphy to detect possible silent myocardial ischemia." | 3.69 | Macrovascular disease is associated with increased plasma apolipoprotein A-IV levels in NIDDM. ( Brun, JM; Cohen, M; Gambert, P; Lagrost, L; Petit, JM; Vaillant, G; Vergès, BL, 1997) |
| "In these patients with type 2 diabetes and a history of TIA, patterns of platelet inhibition differed significantly according to whether treatment was with ER-DP+ASA or clopidogrel with or without ASA." | 2.73 | Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-b ( Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL, 2008) |
| "Nineteen consecutive patients with type 2 diabetes and coronary artery disease entered the study." | 2.70 | Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. ( Avogaro, A; Bagolin, E; Negut, C; Palisi, M; Scognamiglio, R; Tiengo, A; Vigili de Kreutzenberg, S, 2002) |
| "Therefore, glibenclamide treatment of Type 2 diabetes mellitus may have hazardous cardiovascular effects when used under conditions of ischaemia." | 2.70 | Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients. ( Abbink, EJ; Jansen van Rosendaal, A; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ, 2002) |
| "Seventy-six patients with type-2 diabetic nephropathy, who had normal renal function tests were randomized into the 4 groups; each group (n = 19) received one of the following treatments: aspirin (1000 mg), dipyridamole (750 mg), their combination or placebo daily for 2 months." | 2.70 | A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. ( Khajehdehi, P; Mostafavi, H; Roozbeh, J, 2002) |
| "A total of 5308 patients with type 2 diabetes were identified by the National Health Insurance from 1998 to 2000 and followed up until 2013." | 1.72 | Antiplatelet agents aspirin and dipyridamole, and the risk of different carcinoma in patients with type 2 diabetes mellitus: A Taiwan retrospective cohort study. ( Hsu, WH; Huang, HY; Lee, MY; Liang, HL; Lu, TW; Sung, YW, 2022) |
| "The dipyridamole-CF ratio was also lower in diabetic patients than in nondiabetic patients (2." | 1.38 | Effects of type 2 diabetes mellitus on coronary microvascular function and myocardial perfusion in patients without obstructive coronary artery disease. ( Acampa, W; Capasso, E; Casaretti, L; Cuocolo, A; D'Amore, C; Esposito, G; Esposito, R; Galderisi, M; Gargiulo, P; Leosco, D; Lo Iudice, F; Marciano, C; Perrone-Filardi, P; Rengo, G; Savarese, G, 2012) |
| "Myocardial ischemia is frequently asymptomatic, thus leading to a late diagnosis and worse prognosis." | 1.34 | Coronary artery disease in asymptomatic type-2 diabetic women. A comparative study between exercise test, cardiopulmonary exercise test, and dipyridamole myocardial perfusion scintigraphy in the identification of ischemia. ( Alves, A; Carvalho, AC; Mastrocolla, L; Meneghelo, R; Paola, AA; Piegas, LS; Rodrigues, F; Smanio, PE; Tebexreni, AS; Thom, A, 2007) |
| "Osteoprotegerin (OPG) is an inhibitor of osteoclastogenesis, which has been recently involved in atherosclerosis." | 1.33 | Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. ( Avignon, A; Cristol, JP; Dupuy, AM; Elaerts, S; Piot, C; Sultan, A, 2005) |
| "The prevalence of type 2 diabetes mellitus is rapidly increasing." | 1.33 | Tissue Doppler imaging for the detection and quantitation of myocardial dysfunction in patients with type 2 diabetes mellitus. ( Dounis, V; Hansen, A; Malmberg, K; Rydén, L; Thrainsdottir, IS; Von Bibra, H, 2005) |
| "An all the patients with left ventricular hypertrophy (LVH) had decreased CFVR whose values with the myocardial mass index above 130 g/m2 were significantly less than those in the absence of LVH." | 1.32 | [Coronary flow vasodilator reserve in patients with type 2 diabetes mellitus-associated arterial hypertension]. ( Efimova, EV; Karpov, RS; Koshel'skaia, OA; Ocheredko, NA; Panafidin, AV; Soldatenko, MV, 2004) |
| "Nineteen patients with NIDDM and microvascular angina, 18 patients with NIDDM and CAD, and 17 age-matched control subjects were studied." | 1.31 | Coronary microangiopathy in type 2 diabetic patients: relation to glycemic control, sex, and microvascular angina rather than to coronary artery disease. ( Nagai, R; Ohtake, T; Ohtomo, K; Shin, WS; Yamada, N; Yang, W; Yokoyama, I; Yonekura, K, 2000) |
| "The diazoxide-mediated increase in the forearm blood flow ratio (infused/control arm) was significantly less pronounced after glibenclamide than after acarbose (290 +/- 58% and 561 +/- 101% respectively; P<0." | 1.31 | Vascular K(ATP) channel blockade by glibenclamide, but not by acarbose, in patients with Type II diabetes. ( Abbink, EJ; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ; van Rosendaal, AJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.71) | 18.7374 |
| 1990's | 9 (25.71) | 18.2507 |
| 2000's | 20 (57.14) | 29.6817 |
| 2010's | 3 (8.57) | 24.3611 |
| 2020's | 1 (2.86) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, HY | 1 |
| Lu, TW | 1 |
| Liang, HL | 1 |
| Hsu, WH | 1 |
| Sung, YW | 1 |
| Lee, MY | 1 |
| De Lorenzo, A | 2 |
| Lima, RS | 2 |
| Lièvre, MM | 1 |
| Moulin, P | 1 |
| Thivolet, C | 1 |
| Rodier, M | 1 |
| Rigalleau, V | 1 |
| Penfornis, A | 1 |
| Pradignac, A | 1 |
| Ovize, M | 1 |
| Marciano, C | 1 |
| Galderisi, M | 1 |
| Gargiulo, P | 1 |
| Acampa, W | 1 |
| D'Amore, C | 1 |
| Esposito, R | 1 |
| Capasso, E | 1 |
| Savarese, G | 1 |
| Casaretti, L | 1 |
| Lo Iudice, F | 1 |
| Esposito, G | 1 |
| Rengo, G | 1 |
| Leosco, D | 1 |
| Cuocolo, A | 2 |
| Perrone-Filardi, P | 1 |
| Valentine, N | 1 |
| Van de Laar, FA | 1 |
| van Driel, ML | 1 |
| Siqueira-Filho, AG | 1 |
| Pantoja, MR | 1 |
| Kjaer, A | 1 |
| Meyer, C | 1 |
| Nielsen, FS | 1 |
| Parving, HH | 1 |
| Hesse, B | 1 |
| Karpov, RS | 1 |
| Koshel'skaia, OA | 1 |
| Soldatenko, MV | 1 |
| Efimova, EV | 1 |
| Ocheredko, NA | 1 |
| Panafidin, AV | 1 |
| Avignon, A | 2 |
| Sultan, A | 2 |
| Piot, C | 2 |
| Elaerts, S | 1 |
| Cristol, JP | 1 |
| Dupuy, AM | 1 |
| Von Bibra, H | 1 |
| Thrainsdottir, IS | 1 |
| Hansen, A | 1 |
| Dounis, V | 1 |
| Malmberg, K | 1 |
| Rydén, L | 1 |
| Scognamiglio, R | 2 |
| Negut, C | 2 |
| Ramondo, A | 1 |
| Tiengo, A | 2 |
| Avogaro, A | 2 |
| Lacourcière, Y | 1 |
| Côté, C | 1 |
| Lefebvre, J | 1 |
| Dumont, M | 1 |
| Mariano-Goulart, D | 1 |
| Daures, JP | 1 |
| Comte, F | 1 |
| Renard, E | 1 |
| Zamrazil, V | 1 |
| Pálová, S | 1 |
| Holá, D | 1 |
| Storto, G | 1 |
| Pellegrino, T | 1 |
| Sorrentino, AR | 1 |
| Luongo, L | 1 |
| Petretta, M | 1 |
| Smanio, PE | 1 |
| Carvalho, AC | 1 |
| Tebexreni, AS | 1 |
| Thom, A | 1 |
| Rodrigues, F | 1 |
| Meneghelo, R | 1 |
| Mastrocolla, L | 1 |
| Alves, A | 1 |
| Piegas, LS | 1 |
| Paola, AA | 1 |
| Carneiro, FS | 1 |
| Giachini, FRC | 1 |
| Lima, VV | 1 |
| Carneiro, ZN | 1 |
| Leite, R | 1 |
| Inscho, EW | 1 |
| Tostes, RC | 1 |
| Webb, RC | 1 |
| Serebruany, VL | 1 |
| Malinin, AI | 1 |
| Pokov, AN | 1 |
| Hanley, DF | 1 |
| Paillole, C | 2 |
| Ruiz, J | 1 |
| Juliard, JM | 2 |
| Leblanc, H | 2 |
| Gourgon, R | 2 |
| Passa, P | 2 |
| Shimonagata, T | 1 |
| Nanto, S | 1 |
| Hori, M | 1 |
| Ohara, T | 1 |
| Kim, Y | 1 |
| Takano, Y | 1 |
| Sakamoto, K | 1 |
| Kamado, K | 1 |
| Kubori, S | 1 |
| Kusuoka, H | 1 |
| Nishimura, T | 1 |
| Vergès, BL | 1 |
| Lagrost, L | 1 |
| Vaillant, G | 1 |
| Petit, JM | 1 |
| Cohen, M | 1 |
| Gambert, P | 1 |
| Brun, JM | 1 |
| Kranidis, A | 1 |
| Zamanis, N | 1 |
| Mitrakou, A | 1 |
| Patsilinakos, S | 1 |
| Bouki, T | 1 |
| Tountas, N | 1 |
| Anthopoulos, P | 1 |
| Raptis, S | 1 |
| Anthopoulos, L | 1 |
| Yokoyama, I | 2 |
| Ohtake, T | 2 |
| Momomura, S | 1 |
| Yonekura, K | 2 |
| Woo-Soo, S | 1 |
| Nishikawa, J | 1 |
| Sasaki, Y | 1 |
| Omata, M | 1 |
| Vanzetto, G | 1 |
| Halimi, S | 1 |
| Hammoud, T | 1 |
| Fagret, D | 1 |
| Benhamou, PY | 1 |
| Cordonnier, D | 1 |
| Denis, B | 1 |
| Machecourt, J | 1 |
| Gaddi, O | 1 |
| Tortorella, G | 1 |
| Picano, E | 1 |
| Pantaleoni, M | 1 |
| Manicardi, E | 1 |
| Varga, A | 1 |
| Moneta, I | 1 |
| Guiducci, U | 1 |
| Yang, W | 1 |
| Shin, WS | 1 |
| Yamada, N | 1 |
| Ohtomo, K | 1 |
| Nagai, R | 1 |
| Castells, I | 1 |
| Salinas, I | 1 |
| Rius, F | 1 |
| Fraile, M | 1 |
| Rubio, L | 1 |
| Pereferrer, D | 1 |
| Romero, R | 1 |
| Sanmartí, A | 1 |
| Abbink, EJ | 2 |
| Pickkers, P | 2 |
| van Rosendaal, AJ | 1 |
| Lutterman, JA | 2 |
| Tack, CJ | 2 |
| Russel, FG | 2 |
| Smits, P | 2 |
| Vigili de Kreutzenberg, S | 1 |
| Palisi, M | 1 |
| Bagolin, E | 1 |
| Jansen van Rosendaal, A | 1 |
| Khajehdehi, P | 1 |
| Roozbeh, J | 1 |
| Mostafavi, H | 1 |
| Paycha, F | 1 |
| Steg, PG | 1 |
| Philippe, L | 1 |
| Nesto, RW | 1 |
| Watson, FS | 1 |
| Kowalchuk, GJ | 1 |
| Zarich, SW | 1 |
| Hill, T | 1 |
| Lewis, SM | 1 |
| Lane, SE | 1 |
| Zhu, XX | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Strategy Trial Comparing Detection of Silent Ischemia With no Detection of Silent Ischemia in Asymptomatic Patients With Type 2 Diabetes Mellitus. Effects on Cardiovascular Events.[NCT00627783] | 642 participants (Actual) | Interventional | 2000-12-31 | Terminated (stopped due to Poor recruiting status) | |||
| Functional and Anatomic Imaging Versus No Testing in Asymptomatic High-risk Diabetic Patients[NCT04388280] | 400 participants (Anticipated) | Interventional | 2021-01-28 | Recruiting | |||
| Randomized Trial to Evaluate the Effects of Two Different Nutraceutical Therapies on Endothelial Function, Platelet Aggregation, and Coronary Flow Reserve in Hypercholesterolemic Patients at Moderate Cardiovascular Risk[NCT02969070] | 28 participants (Actual) | Interventional | 2016-11-30 | Completed | |||
| A Phase 2, Investigator-Initiated, Feasibility Study to Evaluate the Mechanisms of Coronary Endothelial Dysfunction Imaged As Resting Myocardial Perfusion Heterogeneity After Endothelin Receptor Blockade With Darusentan[NCT00738049] | Phase 2 | 40 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Improvement of Myocardial Function and Metabolic Syndrome in Type 2 Diabetes Patients by a Low Glycemic and Insulinemic Diet (LOGI®) Compared to the Traditional Low Fat Diet - a Prospective Parallel Group/Cross Over Study[NCT01004757] | 41 participants (Anticipated) | Interventional | 2008-02-29 | Active, not recruiting | |||
| Assessment of the Additive Value of Multislice Computed Tomographic Angiography of the Coronary Arteries in the Prediction of Acute Cardiac Events in Asymptomatic Individuals With Type II Diabetes Mellitus[NCT00321542] | 793 participants (Actual) | Observational | 2006-09-30 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00738049)
Timeframe: 0, 2, 4, and 6 weeks
| Intervention | cc/min/gm (Mean) |
|---|---|
| Darusentan 100mg at Rest | 0.65 |
| Darusentan 100mg at Hyperemia | 1.97 |
| Baseline at Rest | 0.50 |
| Baseline at Hyperemia | 2.03 |
CFR is calculated as the unitless ratio between hyperemic to resting flow (NCT00738049)
Timeframe: 0, 2, 4, and 6 weeks
| Intervention | no units (Mean) |
|---|---|
| Baseline | 3.52 |
| Darusentan 100mg | 3.04 |
Markovian homogeneity analysis characterizes an image produced by a PET scan by examining the probability that a pixel with a given intensity will have a neighbor with a different intensity. The homogeneity index ranges from >0 to 1, where a value near 0 represents an image with a high probability that neighboring pixels have intensity values that differ greatly, and a value near 1 represents an image with a high probability that neighboring pixels have similar intensity values. (NCT00738049)
Timeframe: 0, 2, 4, and 6 weeks
| Intervention | No units (Mean) |
|---|---|
| Baseline | 0.33 |
| Darusentan 100mg | 0.39 |
2 reviews available for dipyridamole and Diabetes Mellitus, Type 2
7 trials available for dipyridamole and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening.
Topics: Aged; Ambulatory Care; Asymptomatic Diseases; Cause of Death; Chi-Square Distribution; Diabetes Comp | 2011 |
Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening.
Topics: Aged; Ambulatory Care; Asymptomatic Diseases; Cause of Death; Chi-Square Distribution; Diabetes Comp | 2011 |
Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening.
Topics: Aged; Ambulatory Care; Asymptomatic Diseases; Cause of Death; Chi-Square Distribution; Diabetes Comp | 2011 |
Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening.
Topics: Aged; Ambulatory Care; Asymptomatic Diseases; Cause of Death; Chi-Square Distribution; Diabetes Comp | 2011 |
Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction: a PET study of myocardial perfusion in diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cold Temperature; Coronary Circulation; Coronary Disease; | 2003 |
Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-b
Topics: Adult; Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Biomarkers; Clopidogrel; Diabetes Mell | 2008 |
Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes.
Topics: Cardiomyopathies; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipyridamole; Echocardiography, Str | 2002 |
Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.
Topics: Acetylcholine; Adult; Aged; Blood Flow Velocity; Blood Pressure; Body Mass Index; Body Weight; C-Pep | 2002 |
A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy.
Topics: Adult; Aged; Aspirin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipyridamole; Drug Administ | 2002 |
Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group.
Topics: Adult; Aspirin; Blood Pressure; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellit | 1989 |
27 other studies available for dipyridamole and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Antiplatelet agents aspirin and dipyridamole, and the risk of different carcinoma in patients with type 2 diabetes mellitus: A Taiwan retrospective cohort study.
Topics: Aspirin; Carcinoma; Diabetes Mellitus, Type 2; Dipyridamole; Humans; Liver Neoplasms; Platelet Aggre | 2022 |
Reduced heart rate response to dipyridamole as a marker of left ventricular dysfunction in diabetic patients undergoing myocardial perfusion scintigraphy.
Topics: Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipyridamole; Female; Heart Rate; Humans | 2009 |
Effects of type 2 diabetes mellitus on coronary microvascular function and myocardial perfusion in patients without obstructive coronary artery disease.
Topics: Aged; Case-Control Studies; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Cor | 2012 |
Prevalence and prognostic value of perfusion defects detected by stress technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography in asymptomatic patients with diabetes mellitus and no known coronary artery disease.
Topics: Aged; Angina Pectoris; Coronary Circulation; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic A | 2002 |
[Coronary flow vasodilator reserve in patients with type 2 diabetes mellitus-associated arterial hypertension].
Topics: Coronary Artery Disease; Coronary Circulation; Diabetes Mellitus, Type 2; Dipyridamole; Echocardiogr | 2004 |
Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients.
Topics: Adrenergic beta-Agonists; Aged; Biomarkers; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic An | 2005 |
Tissue Doppler imaging for the detection and quantitation of myocardial dysfunction in patients with type 2 diabetes mellitus.
Topics: Age Factors; Aged; Cardiomyopathies; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diastole; Dip | 2005 |
Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus.
Topics: Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Diabetes Mellitus, Type 2; Diab | 2006 |
Noninvasive detection of silent coronary artery disease in patients with essential hypertension, alone or associated with type 2 diabetes mellitus, using dipyridamole stress 99mtechnetium-sestamibi myocardial perfusion imaging.
Topics: Aged; Coronary Artery Disease; Coronary Circulation; Diabetes Mellitus, Type 2; Dipyridamole; Exerci | 2006 |
Myocardial perfusion imaging and cardiac events in a cohort of asymptomatic patients with diabetes living in southern France.
Topics: Aged; Angina Pectoris; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipyr | 2006 |
[The meaning of the combination of fibrinogen, micro/macroalbuminuria and atheromatosis in the carotid bloodstream for the evaluation of the abnormal finding of the stress myocardial SPECT in the asymptomatic 2nd type diabetic patients].
Topics: Albuminuria; Atherosclerosis; Carotid Arteries; Carotid Artery Diseases; Coronary Circulation; Coron | 2006 |
Estimation of coronary flow reserve by sestamibi imaging in type 2 diabetic patients with normal coronary arteries.
Topics: Aged; Blood Flow Velocity; Coronary Artery Disease; Coronary Vessels; Diabetes Mellitus, Type 2; Dia | 2007 |
Coronary artery disease in asymptomatic type-2 diabetic women. A comparative study between exercise test, cardiopulmonary exercise test, and dipyridamole myocardial perfusion scintigraphy in the identification of ischemia.
Topics: Adult; Aged; Aged, 80 and over; Brazil; Chi-Square Distribution; Coronary Angiography; Coronary Arte | 2007 |
Adenosine actions are preserved in corpus cavernosum from obese and type II diabetic db/db mouse.
Topics: Acetylcholine; Adenosine; Adenosine Kinase; Animals; Diabetes Mellitus, Type 2; Dipyridamole; Diseas | 2008 |
Detection of coronary artery disease in diabetic patients.
Topics: Adult; Aged; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiop | 1995 |
A case of hypertensive-diabetic cardiomyopathy demonstrating left ventricular wall motion abnormality.
Topics: Cardiomyopathies; Coronary Angiography; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipyridamo | 1996 |
Macrovascular disease is associated with increased plasma apolipoprotein A-IV levels in NIDDM.
Topics: Apolipoproteins A; Biomarkers; Blood Glucose; Blood Pressure; Cerebrovascular Disorders; Cholesterol | 1997 |
Coronary microcirculation evaluation with transesophageal echocardiography Doppler in type II diabetics.
Topics: Age Factors; Blood Flow Velocity; Body Mass Index; Case-Control Studies; Coronary Circulation; Coron | 1997 |
Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Coronary Vessels; Diabetes Mellitus, Type 2; Dipyridamol | 1998 |
Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography.
Topics: Activities of Daily Living; Aged; Analysis of Variance; Cardiovascular Diseases; Cholesterol; Choles | 1999 |
Diagnostic and prognostic value of vasodilator stress echocardiography in asymptomatic Type 2 diabetic patients with positive exercise thallium scintigraphy: a pilot study.
Topics: Coronary Angiography; Diabetes Mellitus, Type 2; Dipyridamole; Echocardiography; Exercise Test; Fema | 1999 |
Coronary microangiopathy in type 2 diabetic patients: relation to glycemic control, sex, and microvascular angina rather than to coronary artery disease.
Topics: Adult; Aged; Blood Glucose; Coronary Angiography; Coronary Circulation; Coronary Disease; Diabetes M | 2000 |
Inducible myocardial ischaemia in asymptomatic Type 2 diabetic patients.
Topics: Adult; Aged; Albuminuria; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Nephr | 2000 |
Vascular K(ATP) channel blockade by glibenclamide, but not by acarbose, in patients with Type II diabetes.
Topics: Acarbose; Acetylcholine; Cross-Over Studies; Diabetes Mellitus, Type 2; Diazoxide; Dipyridamole; Dou | 2002 |
Non-invasive identification of severe coronary artery disease in patients with long-standing diabetes mellitus.
Topics: Coronary Angiography; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabet | 1992 |
Silent myocardial ischemia and infarction in diabetics with peripheral vascular disease: assessment by dipyridamole thallium-201 scintigraphy.
Topics: Adult; Aged; Aged, 80 and over; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Diabete | 1990 |
[Effect of danshan and persantin on the alteration of platelet aggregation and microcirculation in diabetics].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipyridamole; Drug Combinations; Drugs, Chinese Herbal; Fema | 1985 |